Methods for promoting myelination and for treating demyelinating diseases

Patent · Tue Jun 04 00:00:00 EDT 2024

OSTI ID:2542244

Lairson, Luke; Beyer, Brittney; Fang, Mingliang; Siuzdak, Gary

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.

• Research Organization: Scripps Research Institute, San Diego, CA (United States); Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
• Sponsoring Organization: USDOE; National Institutes of Health (NIH)
• DOE Contract Number: FG02-07ER64325; AC02-05CH11231
• Other Award/Contract Number: GM114368; EY017540; MH062261; DA026146; OD016357
• Assignee: The Scripps Research Institute (Village of La Jolla, CA)
• Patent Number(s): 11,998,602
• Application Number: 16/978,558
• OSTI ID: 2542244
• Country of Publication: United States
• Language: English